Asacol (Mesalamine Delayed-Release Tablets) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 25, 2012

Asacol

Ulcerative Colitis »

What is Ulcerative Colitis?

Ulcerative colitis is a chronic inflammation of the large intestine (colon). The colon is the part of the digestive system where waste material is stored. The rectum is the end of the colon adjacent to the anus. In patients with ulcerative colitis, ulcers and inflammation of the inner lining of the colon lead to symptoms of abdominal pain, diarrhea, and rectal bleeding.

Ulcerative colitis is closely related to another condition of inflammation of the intestines called Crohn's disease. Together, they are frequently referred to as inflammatory bowel disease (IBD). Ulcerative colitis and Crohn's diseases are chronic conditions that can last years to decades. They affect approximately 500,000 to 2 million people In the United States. Men and women are affected equally. They most commonly begin during adolescence and early adulthood, but they also can begin during childhood and later in life.

...

Read the Ulcerative Colitis article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Asacol

Ulcerative Colitis Slideshow Pictures

Inflammatory Bowel Disease Slideshow

Digestive Disease Myths Slideshow

font size

OVERDOSE

Two cases of pediatric overdosage have been reported. A 3-year-old male who ingested 2 grams of Asacol (mesalamine delayed-release tablets) tablets was treated with ipecac and activated charcoal; no adverse events occurred. Another 3-year-old male, approximately 16 kg, ingested an unknown amount of a maximum of 24 grams of Asacol crushed in solution (i.e., uncoated mesalamine); he was treated with orange juice and activated charcoal, and experienced no adverse events. In dogs, single doses of 6 grams of delayed-release Asacol (mesalamine delayed-release tablets) tablets resulted in renal papillary necrosis but were not fatal. This was approximately 12.5 times the recommended human dose (based on a dose of 2.4 g/day in a 50 kg person). Single oral doses of uncoated mesalamine in mice and rats of 5000 mg/kg and 4595 mg/kg, respectively, or of 3000 mg/kg in cynomolgus monkeys, caused significant lethality.

CONTRAINDICATIONS

Asacol (mesalamine delayed-release tablets) tablets are contraindicated in patients with hypersensitivity to salicylates or to any of the components of the Asacol (mesalamine delayed-release tablets) tablet.

Last reviewed on RxList: 6/17/2010
This monograph has been modified to include the generic and brand name in many instances.